Loading...
Docoh

Bristol-Myers Squibb (BMY)

News

From Benzinga Pro
Bristol Myers Squibb Data At ASCO And EHA 2022 Highlight Progress In Transforming Treatment For Patients With Cancer And Blood Disorders
19 May 22
Biotech, News, FDA, Events, General
Long-term data from Opdivo plus Yervoy-based combinations demonstrate durable survival in metastatic non-small cell lung cancer (NSCLC) and metastatic melanoma, including results from landmark five-year analysis of
9 Health Care Stocks With Whale Alerts In Today's Session
18 May 22
Options
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Immatics Announced First Patient Treated with ACTengine IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo (nivolumab) in Patients with Advanced Solid Tumors
18 May 22
News
Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the first patient has been dosed in the IMA203 and nivolumab combination Phase 1b dose expansion cohort.
Looking At Bristol-Myers Squibb's Recent Whale Trades
17 May 22
Options, Markets
A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 14 strange trades.
Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Raises Price Target to $70
17 May 22
News, Price Target, Analyst Ratings
Wells Fargo analyst Mohit Bansal maintains Bristol-Myers Squibb (NYSE:BMY) with a Equal-Weight and raises the price target from $65 to $70.
Michael Burry Is Betting Against Apple: Here's The Size Of 'The Big Short' Investor's Stake
16 May 22
News, Short Sellers, Trading Ideas
Michael Burry has been known to take large positions against companies he thinks are overvalued.
Bristol Myers' Opdivo+Yervoy Fails To Meet Survival Endpoint In Untreated Urothelial Cancer
16 May 22
Biotech, Large Cap, News, Health Care, General
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
13 May 22
Biotech, Earnings, News, Penny Stocks, Health Care, Contracts, Small Cap, FDA, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Bristol Myers Reports LOTTE Corp. To Buy Co.'s Manufacturing Facility In East Syracuse, New York, No Terms Disclosed
13 May 22
News, Asset Sales
-- East Syracuse Site to Serve as the LOTTE Center for North America Operations for LOTTE’s biologics contract development and manufacturing organization (CDMO) business -- NEW YORK & SEOUL--(BUSINESS WIRE)--
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
12 May 22
Biotech, Large Cap, News, Health Care, Contracts, Small Cap, General
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
12 May 22
Biotech, Earnings, News, Penny Stocks, Health Care, Financing, Offerings, Contracts, Small Cap, FDA, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
BridgeBio Eligible To Receive Up To $905M From Bristol Myers Squibb In Agreement
12 May 22
News, Contracts, FDA
- BridgeBio is eligible to receive up to $905 million, including an upfront payment of $90 million, and up to $815 million in additional milestone payments and royalties -SHP2 inhibitor deal
Bridgebio Announces Exclusive License Agreement With Bristol Myers Squibb To Develop And Commercialize BBP-398, A Potentially Best-In-Class SHP2 Inhibitor, In Oncology
12 May 22
News, Contracts, FDA
BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology - BridgeBio is eligible to receive up to $905
Bristol Myers Squibb Announces New Two-year Deucravacitinib Data Reinforce Durable Efficacy And Consistent Safety Profile In Treatment Of Moderate To Severe Plaque Psoriasis
12 May 22
Biotech, News, FDA, General
POETYK PSO long-term extension trial results show maintenance of efficacy response through up to two years of treatment Results add to the growing body of evidence on deucravacitinib, a potential new oral
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
10 May 22
Biotech, Earnings, M&A, News, Penny Stocks, Guidance, Health Care, Financing, Offerings, Small Cap, FDA, Management, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
9 Health Care Stocks With Whale Alerts In Today's Session
6 May 22
Options
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Peering Into Bristol-Myers Squibb's Recent Short Interest
6 May 22
Short Sellers, Short Ideas, Trading Ideas
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 8.23% since its last report. The company recently reported that it has 47.34 million shares sold short, which is 2.23% of all regular shares that are available for trading.
Check Out What Whales Are Doing With BMY
5 May 22
Options, Markets
Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
BMO Capital Maintains Outperform on Bristol-Myers Squibb, Raises Price Target to $92
2 May 22
News, Price Target, Analyst Ratings
BMO Capital analyst Evan Seigerman maintains Bristol-Myers Squibb (NYSE:BMY) with a Outperform and raises the price target from $87 to $92.
Bristol-Myers Squibb's Return On Capital Employed Overview
2 May 22
Earnings
According to Benzinga Pro, during Q1, Bristol-Myers Squibb (NYSE:BMY) earned $1.28 billion, a 45.91% increase from the preceding quarter. Bristol-Myers Squibb's sales decreased to $11.65 billion, a 2.81% change since Q4.

Press releases

From Benzinga Pro
Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders
19 May 22
Press Releases
Long-term data from Opdivo plus Yervoy-based combinations demonstrate durable survival in metastatic non-small cell lung cancer (NSCLC) and metastatic melanoma, including results from landmark five-year analysis of
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
18 May 22
Small Cap, Opinion, Press Releases
FinancialNewsMedia.com News Commentary PALM BEACH, Fla., May 18, 2022 /PRNewswire/ -- Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30
Bristol Myers Squibb Provides Update on CheckMate -901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carcinoma
16 May 22
Press Releases
Bristol Myers Squibb (NYSE:BMY) today announced the Phase 3 CheckMate -901 trial, comparing Opdivo (nivolumab) plus Yervoy (ipilimumab) to standard-of-care chemotherapy as a first-line treatment for patients with
LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New York
13 May 22
Press Releases
-- East Syracuse Site to Serve as the LOTTE Center for North America Operations for LOTTE's biologics contract development and manufacturing organization (CDMO) business -- Bristol Myers Squibb (NYSE:BMY) and LOTTE
New Two-Year Deucravacitinib Data Reinforce Durable Efficacy and Consistent Safety Profile in Treatment of Moderate to Severe Plaque Psoriasis
12 May 22
Press Releases
POETYK PSO long-term extension trial results show maintenance of efficacy response through up to two years of treatment Results add to the growing body of evidence on deucravacitinib, a potential new oral treatment
Lifshitz Law PLLC. Announces Investigations of AppHarvest, Inc. (NASDAQGS: APPH), Bristol-Myers Squibb Company (NYSE: BMY), InnovAge Holding Inc. (NASDAQGS: INNV), Meta Platforms, Inc. f/k/a Facebook, Inc. (NASDAQGS: FB)
11 May 22
News, Legal, Press Releases
NEW YORK, May 11, 2022 (GLOBE NEWSWIRE) -- AppHarvest, Inc. (NASDAQ:APPH) Lifshitz Law PLLC announces that a class action complaint was filed against APPH alleging Defendants failed to disclose to investors: (1)
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation
10 May 22
Contracts, Press Releases
8-YEAR EXTENSION AND EXPANSION OF COLLABORATION TO DEVELOP PIPELINE OF MOLECULAR GLUE DEGRADERSCOLLABORATION LEVERAGES EVOTEC'S PROPRIETARY EVO PANOMICS AND EVO PANHUNTER PLATFORMS COVERING HIGH-PERFORMANCE MULTI-OMICS
Bristol Myers Squibb to Participate in Bank of America Securities 2022 Healthcare Conference
4 May 22
Press Releases
Bristol Myers Squibb (NYSE:BMY) today announced that the company will take part in a fireside chat at the Bank of America Securities 2022 Healthcare Conference in Las Vegas, Nevada on Wednesday, May 11, 2022. Adam
Thinking about trading options or stock in Intel Corp, Bristol-Myers Squibb, AbbVie, Teladoc Health, or Roku?
29 Apr 22
Opinion, Press Releases
NEW YORK, April 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INTC, BMY, ABBV, TDOC, and ROKU.
Bristol Myers Squibb Reports First Quarter Financial Results for 2022
29 Apr 22
Press Releases
Reports First Quarter Revenues of $11.6 Billion, an Increase of 5% YoY; or 7% When Adjusted for Foreign Exchange Posts First Quarter Earnings Per Share of $0.59 and Non-GAAP EPS of $1.96; Includes Net Impact of
U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms
28 Apr 22
Press Releases
Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients
FSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory Board
21 Apr 22
Press Releases
Mr. Allan, the 2017 winner of the prestigious Julia Levy Award, to collaborate with 2021 Julia Levy Award winner Dr. Lakshmi P. Kotra, CEO of FSD Pharma subsidiary Lucid Psycheceuticals FSD Pharma Inc. (NASDAQ:HUGE)
EDP Renewables and Bristol Myers Squibb Execute Power Purchase Agreement for the Cattlemen Solar Park
21 Apr 22
News, Contracts, Press Releases
Houston, Texas, April 21, 2022 (GLOBE NEWSWIRE) -- EDP Renewables SA (EDPR), through its fully owned subsidiary EDP Renewables North America LLC (EDPR NA), and Bristol Myers Squibb (NYSE:BMY) have executed a 15-year
Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)
14 Apr 22
Press Releases
PRINCETON, N.J. and SAN FRANCISCO, April 14, 2022 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) and Bristol Myers Squibb (NYSE:BMY) today announced that based on results from pre-planned analyses of two late-stage
Cognitive Drugs Market Expected Reach Revenues Of $21 Billion in 2027
13 Apr 22
Small Cap, Opinion, Press Releases
PALM BEACH, Fla., April 13, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent that
Secarna Pharmaceuticals' Strategic Partner Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb
12 Apr 22
News, Press Releases
The programme designation is based on an antisense-based approach which triggers a US$ 16 M payment to Evotec by Bristol Myers SquibbEvotec sources LNAplusTM antisense technology through a strategic partnership with
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
11 Apr 22
Press Releases
When administered before surgery, three cycles of Opdivo in combination with chemotherapy reduced the risk of disease recurrence, progression or death by 37% and showed an encouraging early trend in overall
Bristol Myers Squibb Foundation Honors Diversity and Health Equity Leader By Naming Diversity in Clinical Trials Training Program After Him; Welcomes Gilead Sciences as Program Supporter
11 Apr 22
Press Releases
The groundbreaking, uniquely robust Robert A. Winn Diversity in Clinical Trials Award Program is on track to train more than 500 individuals from diverse backgrounds by 2027 The Bristol Myers Squibb Foundation (BMSF),
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma
5 Apr 22
Press Releases
Breyanzi represents a differentiated CAR T cell therapy with demonstrated rapid and durable complete responses and a manageable safety profile Approval of Breyanzi is based on results from TRANSCEND WORLD, and
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with...
5 Apr 22
Press Releases
Opdivo with chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy alone in this patient population; approval based on Phase 3 results from